Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 98.56%.

  • Lineage Cell Therapeutics' FCF Margin rose 575400.0% to 98.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 193.0%, marking a year-over-year increase of 714300.0%. This contributed to the annual value of 249.05% for FY2024, which is 778400.0% up from last year.
  • Lineage Cell Therapeutics' FCF Margin amounted to 98.56% in Q3 2025, which was up 575400.0% from 200.83% recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year FCF Margin high stood at 417.38% for Q1 2022, and its period low was 1901.53% during Q1 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' median FCF Margin value was 234.0% (recorded in 2024), while the average stood at 355.91%.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' FCF Margin plummeted by -9217700bps in 2021, and later skyrocketed by 23189100bps in 2022.
  • Lineage Cell Therapeutics' FCF Margin (Quarter) stood at 12.04% in 2021, then crashed by -3495bps to 432.74% in 2022, then skyrocketed by 32bps to 292.62% in 2023, then grew by 20bps to 234.0% in 2024, then soared by 58bps to 98.56% in 2025.
  • Its last three reported values are 98.56% in Q3 2025, 200.83% for Q2 2025, and 331.76% during Q1 2025.